Frequency and new-onset rates of nausea and fatigue in ¹⁷⁷Lu-PSMA therapy with standardized premedication
Wolfram A. Bosbach, Karene Sriramachandran, Nasir Gözlügöl, Axel Rominger, Marco Cuzzocrea, Sabin G. Pop, Gaetano Paone, Irene A. Burger, Ali Afshar-Oromieh · Nuklearmedizin - NuclearMedicine · 2026 · Heft 05 · S. 303-311
Bibliografische Angaben
Zusammenfassung
Abstract Aim PSMA-based radioligand therapy (PSMA-RLT) for metastatic castration-resistant prostate cancer (mCRPC) is associated with nausea, vomiting, and fatigue. We evaluated whether standardized premedication with glucocorticoids and antiemetics reduces these side effects. Methods In this retrospective multicentre study, 67 mCRPC patients received 322 cycles of 177Lu-PSMA-617 at three Swiss centres. All patients received 8 mg dexamethasone and 8 mg ondansetron intravenously 30 minutes before therapy. Side effects were assessed using study-specific questionnaires (195/322 returned; 61%). Baseline symptoms wer…
